GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Cash Conversion Cycle

Journey Medical (Journey Medical) Cash Conversion Cycle : -0.07 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Journey Medical's Days Sales Outstanding for the three months ended in Mar. 2024 was 87.61.
Journey Medical's Days Inventory for the three months ended in Mar. 2024 was 139.14.
Journey Medical's Days Payable for the three months ended in Mar. 2024 was 226.82.
Therefore, Journey Medical's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was -0.07.


Journey Medical Cash Conversion Cycle Historical Data

The historical data trend for Journey Medical's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Cash Conversion Cycle Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
154.76 153.20 55.53 -88.81 -111.85

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -170.47 -181.51 -240.16 -130.62 -0.07

Competitive Comparison of Journey Medical's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Journey Medical's Cash Conversion Cycle falls into.



Journey Medical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Journey Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=100.1+166.79-378.74
=-111.85

Journey Medical's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=87.61+139.14-226.82
=-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Journey Medical  (NAS:DERM) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Journey Medical Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Journey Medical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

This Insider Just Sold Shares of Journey Medical Corp

By GuruFocus Research GuruFocus Editor 05-20-2023